文章摘要
丁冠男,李树人,潘振祥,高成杰,麻海春.巴曲亭对低分子肝素抗凝全髋置换术患者出血量及凝血功能影响的研究[J].中华流行病学杂志,2014,35(6):737-740
巴曲亭对低分子肝素抗凝全髋置换术患者出血量及凝血功能影响的研究
Effects of batroxobin on perioperative blood loss and coagulation in patients with low molecular weight heparin when undergoing the total hip replacement
收稿日期:2013-12-31  出版日期:2014-09-02
DOI:
中文关键词: 低分子肝素  巴曲亭  全髋关节置换术  出血量
英文关键词: Low molecular weight heparin  Batroxobin  Total hip replacement  Blood loss
基金项目:
作者单位E-mail
丁冠男 100050 北京, 首都医科大学附属北京友谊医院  
李树人 100050 北京, 首都医科大学附属北京友谊医院 guannanding@sina.com 
潘振祥 吉林大学附属第二医院  
高成杰 济南军区总医院  
麻海春 吉林大学附属第一医院  
摘要点击次数: 2551
全文下载次数: 1149
中文摘要:
      目的 探讨巴曲亭与低分子肝素的相互作用,观察巴曲亭用于骨科低分子肝素抗凝全髋置换术患者的疗效和安全性。方法 采用多中心、随机、双盲对照研究设计,按照1 ∶ 1 比例纳入ASAⅠ~Ⅲ 级单侧全髋置换术患者240 例,试验组(低分子肝素+巴曲亭组)120 例,对照组(低分子肝素组)120 例,比较两组患者的术中出血量、术后引流量,并检测术前、术中及术后24h 凝血酶原时间(PT)、部分凝血活酶时间(APTT)、纤维蛋白原(FIB)水平变化,两组患者均于术前及术后第3 天行下肢静脉多普勒彩超检查,并记录术后住院时间。结果 最终试验组119 例、对照组120 例纳入数据分析。试验组术中出血量(422.64 ml)明显低于对照组(667.67 ml)(P<0.01),两组患者术毕PT、APTT均较给药前有所延长(P<0.01),红细胞(RBC)、Hb、红细胞比容积(Hct)、血小板水平均较给药前明显下降(P<0.01),组间比较差异无统计学意义(P>0.05)。术后第3 天下肢多普勒彩超检查均未发现下肢深静脉血栓。两组患者住院期间均无不良事件,且实际住院时间的差异无统计学意义(P>0.05)。结论 全髋置换术中使用巴曲亭不受低分子肝素的抑制,且安全有效,术前5~10 min静脉注射2 U可明显减少患者出(渗)血量。
英文摘要:
      Objective To investigate the interactive effects between batroxobin and low molecular weight heparin(LMWH)in reducing peri-operative blood loss and coagulation function in patients who undergone the total hip replacement surgery. Methods 240 ASA Ⅰ - Ⅲ patients received 4 000 IU LMWH 12 hours preoperatively before undergoing the total hip replacement operation,were randomly divided into two groups:testing group(Group A,n=120)and control group(Group B,n=120)receiving 2 U batroxobin or 50 mg mannitol 10 minutes before incision respectively. Perioperative blood loss,postoperative 24 hours drainage and blood routine test, prothrombin time(PT),activated partial thromboplastin time(APTT)and fibrinogen(FIB)were measured respectively. Deep vein thrombosis (DVT) were measured through color Doppler B-ultrasound 3 days after the operation. Results The perioperative blood loss in Group A (422.64 ml)was less than that in Group B(667.67 ml)(P<0.01)while red blood cell,hemoglobin, red blood cell volume and platelet were decreasing after operation in both groups but no significant difference was found between the two groups(P>0.05). There were no drug-related adverse effects found in the two groups,neither the difference in hospitalization between the two groups(P> 0.05). Conclusion Batroxobin(2 U)could reduce the perioperative blood loss in patients with LMWH who had undergone the total hip replacement operation but did not show adverse effect on DVT.
查看全文   Html全文     查看/发表评论  下载PDF阅读器
关闭